Acamprosate in the treatment of alcohol dependence: clinical and economic considerations (Q36998827)

17 August 2017

1 reference

title

Acamprosate in the treatment of alcohol dependence: clinical and economic considerations (English)

1 reference

17 August 2017

1 reference

Barbara J Mason

1 reference

17 August 2017

Rebecca Crean

series ordinal

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

1465-1477

1 reference

Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Disulfiram treatment of alcoholism. A Veterans Administration cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Barriers to the use of medications to treat alcoholism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Medications to treat heavy drinking: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Clinical pharmacokinetics of acamprosate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Chronic Acamprosate Eliminates the Alcohol Deprivation Effect While Having Limited Effects on Baseline Responding for Ethanol in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

The role of glutamatergic neurotransmission in the pathophysiology of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Cytotoxic effect of alcohol-withdrawal on primary cultures of cortical neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Neurotoxicity of polyamines and pharmacological neuroprotection in cultures of rat cerebellar granule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Polyamines contribute to ethanol withdrawal-induced neurotoxicity in rat hippocampal slice cultures through interactions with the NMDA receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Potential neuroprotective effects of acamprosate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

The neurobiology of addiction: a neuroadaptational view relevant for diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Central effects of acamprosate: part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Does acamprosate improve reduction of drinking as well as aiding abstinence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Pharmacotherapy of dual substance abuse and dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Polysubstance use among alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Insomnia, self-medication, and relapse to alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Sleep abnormalities during abstinence in alcohol-dependent patients. Aetiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

The role of postsynaptic calcium in the induction of long-term potentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Cognitive impairment among alcoholics: impact on drink refusal skill acquisition and treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Implications of cognitive impairment for the treatment of alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Effects of acamprosate on psychomotor performance and driving ability in abstinent alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Economic cost of alcohol and drug abuse in the United States, 1992: a report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

The excess medical cost and health problems of family members of persons diagnosed with alcohol or drug problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1465

10.1586/14737175.7.11.1465

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference